Published Paper Details:

The gradual decrease of renal function that results in chronic kidney disease (CKD) is a degenerative disorder that can cause a number of issues. Anaemia is one of these issues that affects CKD patients often and significantly. This presentation seeks to present a thorough discussion of the impact of anaemia on CKD patients, including its pathogenesis, clinical symptoms, and implications for patient outcomes. Beyond symptomatology, anaemia has an impact on CKD patients. It has been linked to a higher risk of cardiovascular events, more hospital stays, worse cognitive function, lower quality of life, and higher death rates. Erythropoiesis-stimulating medications and iron supplements are often used to treat anaemia in people with chronic kidney disease (CKD), although the best strategy is still under investigation. This study also emphasises the difficulties in detecting and treating anaemia in CKD patients. A thorough review that includes test results for erythropoietin, iron studies, and haemoglobin levels is necessary for an accurate diagnosis. Considerations for treatment include controlling iron storage, tailoring therapy depending on patient characteristics, and keeping an eye out for any potential side effects. In conclusion, anaemia is a frequent and serious consequence in CKD patients that significantly affects their health and quality of life. To improve patient outcomes and quality of life, anaemia in CKD must be identified early and managed appropriately. To lessen the burden of anaemia in this susceptible patient group, further research is required to improve diagnostic standards, optimise therapeutic treatments, and investigate innovative treatment methods.